168
Views
7
CrossRef citations to date
0
Altmetric
Case Report

Successful Treatment of Serious Meningitis Caused by Extremely Carbapenem-Resistant Enterobacter cloacae (MIC≥16mg/L) with i.v. Meropenem and i.v. Amikacin Plus Intraventricular Amikacin

ORCID Icon, , , &
Pages 3765-3770 | Published online: 02 Dec 2019

References

  • Hu F, Gou Y, Zhu D, et al. Antimicrobial resistance profile of clinical isolates in hospitals across China: report from the CHINET Surveillance Program, 2017. Chin J Infect Chemother. 2018;18(03):241–251.
  • Holyk A, Belden V, Lee JJ, et al. Ceftazidime/avibactam use for carbapenem-resistant Klebsiella pneumoniae meningitis: a case report. J Antimicrob Chemother. 2018;73(1):254–256. doi:10.1093/jac/dkx35829040635
  • Morrill HJ, Pogue JM, Kaye KS, LaPlante KL. Treatment options for carbapenem-resistant enterobacteriaceae infections. Open Forum Infect Dis. 2015;2(2):ofv050. doi:10.1093/ofid/ofv05026125030
  • Daikos GL, Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin Microbiol Infect. 2011;17(8):1135–1141. doi:10.1111/j.1469-0691.2011.03553.x21635663
  • Tzouvelekis LS, Markogiannakis A, Piperaki E, Souli M, Daikos GL. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect. 2014;20(9):862–872. doi:10.1111/1469-0691.1269724890393
  • Bassetti M, Peghin M, Pecori D. The management of multidrug-resistant Enterobacteriaceae. Curr Opin Infect Dis. 2016;29(6):583–594. doi:10.1097/QCO.000000000000031427584587
  • Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55(7):943–950. doi:10.1093/cid/cis58822752516
  • Cprek JB, Gallagher JC. Ertapenem-containing double-carbapenem therapy for treatment of infections caused by carbapenem-resistant klebsiella pneumoniae. Antimicrob Agents Chemother. 2016;60(1):669–673. doi:10.1128/AAC.01569-1526552970
  • Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious diseases society of America’s clinical practice guidelines for healthcare-associated ventriculitis and meningitis. Clin Infect Dis. 2017. doi:10.1093/cid/cix152
  • Nau R, Sorgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev. 2010;23(4):858–883. doi:10.1128/CMR.00007-1020930076
  • Molinaro M, Morelli P, De Gregori M, et al. Efficacy of intraventricular amikacin treatment in pan-resistant Pseudomonas aeruginosa postsurgical meningitis. Infect Drug Resist. 2018;11:1369–1372. doi:10.2147/IDR.S16927130214257
  • Lauretti L, D’Alessandris QG, Fantoni M, et al. First reported case of intraventricular tigecycline for meningitis from extremely drug-resistant Acinetobacter baumannii. J Neurosurg. 2017;127(2):370–373. doi:10.3171/2016.6.JNS1635227540902